Results 21 to 30 of about 131,813 (277)

Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 Mice [PDF]

open access: yes, 2013
Backgrounds: Most of the hepatitis C virus (HCV) infections elicit poor immune responses and 75% to 85% of cases become chronic; therefore, the development of an effective vaccine against HCV is of paramount importance.
Behnampour, N.   +5 more
core   +2 more sources

Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs [PDF]

open access: yes, 2012
Hepatitis E virus (HEV), the causative agent of hepatitis E, is primarily transmitted via the fecal-oral route through contaminated water supplies, although many sporadic cases of hepatitis E are transmitted zoonotically via direct contact with infected ...
Córdoba, Laura   +5 more
core   +1 more source

EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA

open access: yesHematology, Transfusion and Cell Therapy, 2021
Objective: Our study aims to evaluate the patients’ immunity regarding childhood vaccination after leukemia treatment and determine the vaccines that require additional doses. Methodology: Sixty-six patients who were followed up with the diagnosis of ALL
Elif KILIC KONTE   +4 more
doaj   +1 more source

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

open access: yes, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
A Olotu   +43 more
core   +5 more sources

To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity

open access: yesViruses, 2021
Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030.
Felicia Schlotthauer   +2 more
doaj   +1 more source

Letter to the Editor regarding the article “Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm”

open access: yesActa Médica Portuguesa, 2017
N/A.
Joana Carvalho e Branco   +2 more
doaj   +1 more source

Comparative study of hydropericardium hepatitis syndrome vaccine in poultry [PDF]

open access: yesIraqi Journal of Veterinary Sciences, 2005
Two commercial types of Hydro pericardium Hepatitis Syndrome (HHS) oily inactivated vaccines were evaluated. The first was (Angavac) French in origin (Merial Co.) & the 2nd is (Nobilis Hepatitis) Holland in origin (Intervet Co.).
F A Jassim, M Y Al-Attar, F A Danial
doaj   +1 more source

Hepatitis A Vaccine Recommendations [PDF]

open access: yesPediatrics, 2007
This Policy Statement was retired July 2010. Since licensure in 1995 of a hepatitis A vaccine, the Centers for Disease Control and Prevention and the American Academy of Pediatrics have been implementing an incremental hepatitis A immunization strategy for children.
openaire   +2 more sources

Hepatitis E, a Vaccine-Preventable Cause of Maternal Deaths

open access: yesEmerging Infectious Diseases, 2012
Hepatitis E virus (HEV) is a major cause of illness and of death in the developing world and disproportionate cause of deaths among pregnant women.
Alain B. Labrique   +6 more
doaj   +1 more source

A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine. [PDF]

open access: yesPLoS ONE, 2017
Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects.
Jingbo Wang   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy